Improving survival in recurrent medulloblastoma
Author Information
Author(s): E Bouffet, F Doz, MC DemaiIle, P Tron, H Roche, D Plantaz, A Thyss, JL Stephan, O Lejars, E Sariban, M BucIon, JM Zucker, M Brunat-Mentigny, JL Bernard, JC Gentet
Primary Institution: Centre Leon Berard, Lyon, France
Hypothesis
The study aims to determine the factors influencing the length of survival in children with recurrent medulloblastoma.
Conclusion
The length of survival in recurrent medulloblastoma is primarily related to specific patterns of relapse and the response to salvage therapy.
Supporting Evidence
- Forty-six out of 116 patients had progressive or recurrent disease.
- The median survival time after progression was 5 months.
- Seventeen patients had asymptomatic relapses detected by the surveillance protocol.
- Patients with isolated relapses had a significantly longer survival than those with combined relapses.
- Patients responding to salvage therapy had a significantly better survival than non-responders.
Takeaway
This study looked at children with recurring brain tumors and found that how and when the tumors come back affects how long kids live after that.
Methodology
The study analyzed patterns of recurrences in three consecutive protocols and included a uniform surveillance program with repeated lumbar punctures and imaging scans.
Limitations
The study is retrospective and involved patients treated in a heterogeneous way.
Participant Demographics
Patients were aged less than 20 years, with a mix of high-risk and low-risk classifications based on disease extent.
Statistical Information
P-Value
p=0.00004
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website